Mounjaro is tirzepatide — a drug approved for type 2 diabetes that happens to cause some of the largest weight loss of any medicine, around 20% in trials. That is why people seek it out for weight loss, even though the version actually approved for obesity is its twin, Zepbound.
So “Mounjaro for weight loss” is usually an off-label story: the same molecule, prescribed for a use it was not branded for. Here is how well it works, how it compares to Zepbound, the side effects, and how access works in Canada.
Does Mounjaro work for weight loss?
Yes — strikingly well. Tirzepatide, the molecule in Mounjaro, produced an average of up to about 20.9% body-weight reduction over 72 weeks in the SURMOUNT-1 obesity trial, and it beat semaglutide head-to-head in SURMOUNT-5 (about 20.2% vs 13.7%). It works by activating two gut-hormone receptors, GLP-1 and GIP, which together curb appetite and slow digestion more than a single-receptor drug like Ozempic.
The nuance: those obesity trials studied tirzepatide as a weight drug (the Zepbound use), but it is the identical molecule in the Mounjaro pen. The weight loss is real regardless of which label is on the box. For the full category context, see the complete GLP-1 drugs guide.
Mounjaro and Zepbound are the same tirzepatide. The weight loss does not care which name is printed on the pen.The fact behind every ‘Mounjaro for weight loss’ search
Mounjaro vs Zepbound
They are the same drug with two brand names and two approved uses: Mounjaro for type 2 diabetes, Zepbound for weight management. Prescribing Mounjaro specifically for weight loss is therefore off-label — legal and common, but technically outside its labelled indication, since Zepbound is the obesity-approved version. If both are available to you, the obesity-branded Zepbound is the on-label route for weight loss. Full breakdown in Zepbound in Canada and Mounjaro vs Ozempic.
How to get it in Canada
Tirzepatide is available in Canada by prescription. A doctor can prescribe it, and it is dispensed through pharmacies. Expect the familiar hurdles: weight-loss use is rarely covered by public plans, private coverage varies, and many people pay out of pocket. For the money picture and alternatives, see weight-loss injections in Canada and Ozempic alternatives in Canada.
Side effects
The common ones are gastrointestinal — nausea, diarrhoea, constipation, vomiting and reflux — worst while the dose is being increased and easing with time. Because tirzepatide is potent, some people find these noticeable. Rare but serious risks include pancreatitis and gallbladder problems, and the class carries a thyroid-tumour warning. Fast loss can also bring muscle loss and facial volume loss. These are reasons it is a prescription drug used under medical supervision.
Mounjaro is a prescription medicine. Dose selection and monitoring are decisions for your doctor, and this article does not provide dosing guidance. Using it for weight loss is off-label and should be discussed with a clinician.
The research-compound angle
Tirzepatide is also sold as a research peptide — at TrueLabs as TZ-2. The research compound is a raw material for in vitro and laboratory study, not the Mounjaro drug: no verified human dose, no sterile formulation, no regulatory oversight. The weight-loss figures above describe the pharmaceutical drug used under medical supervision. See how to spot fake peptides for sourcing background.
Mounjaro weight-loss myths
“Myth: Mounjaro is a dedicated weight-loss drug.”
Mounjaro is approved for type 2 diabetes. The obesity-approved version of tirzepatide is Zepbound. Using Mounjaro for weight loss is off-label.
“Myth: Mounjaro and Zepbound give different results.”
They are the identical molecule, so the weight-loss potential is the same.
“Myth: You keep the weight off after stopping.”
Most of the lost weight tends to return after stopping, as with the whole GLP-1 class.
“Myth: Research tirzepatide is a cheap Mounjaro.”
No. It is an unapproved raw compound for lab use, without dose, formulation or oversight.
For researchers
TrueLabs supplies TZ-2 (tirzepatide) from $73, RT3 (retatrutide) from $90 and Cagrilintide from $40, in CAD for in vitro and laboratory research only. Before ordering, see how to read a peptide COA and the COA library.
FAQ
Tap a question to reveal the answer.
Does Mounjaro work for weight loss?
Yes. Tirzepatide, the molecule in Mounjaro, produced up to about 20.9% weight loss over 72 weeks in the SURMOUNT-1 obesity trial and beat semaglutide head-to-head. The weight loss is substantial.
Is Mounjaro approved for weight loss?
Mounjaro is approved for type 2 diabetes. The obesity-approved version of tirzepatide is Zepbound, so prescribing Mounjaro for weight loss is off-label.
What is the difference between Mounjaro and Zepbound?
They are the same molecule, tirzepatide. Mounjaro is the diabetes brand; Zepbound is the weight-management brand.
How much weight can you lose on Mounjaro?
Trial averages reached about 20.9% at the highest dose over 72 weeks, though individual results vary widely.
How do I get Mounjaro in Canada?
By prescription through a pharmacy. Weight-loss use is often not covered by insurance, so many people pay out of pocket.
What are the side effects?
Mostly gastrointestinal — nausea, diarrhoea, constipation and reflux — worst during dose increases. Serious effects are rarer and are why it needs medical supervision.
Do you regain the weight after stopping?
Typically yes, as with other GLP-1 drugs. It is managed as a long-term treatment.
Is research tirzepatide the same as Mounjaro?
No. Research tirzepatide (TrueLabs TZ-2) is a raw compound for laboratory use, not the regulated, dose-formulated medicine.
Related reading
- Zepbound in Canada
- Mounjaro vs Ozempic
- The complete GLP-1 drugs guide
- Ozempic alternatives in Canada
- Weight-loss injections in Canada
References
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. NEJM
- Aronne LJ, et al. Tirzepatide versus Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. NEJM
- Health Canada. Advisory: unauthorized injectable peptide products, 2025.
This article summarizes published research and regulatory information for information only and is not medical advice. TrueLabs research compounds are sold for in vitro and laboratory research use only and are not intended for human or veterinary use.